SCHEMBL31199048

SCHEMBL31199048

Cc1noc(C)c1-c1cc(NC(=O)c2ccccc2)ccc1OC[C@H]1CCCCN1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
CREBBP Q92793 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
MAPT P10636 1/20 0.40
AKR1C3 P42330 1/20 0.40
P2RY14 Q15391 1/20 0.40
SLC6A2 P23975 1/20 0.40
HRH2 P25021 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2B P41595 1/20 0.40
SLC6A3 Q01959 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
HDAC1 Q13547 1/20 0.39
ALDH1A1 P00352 2/20 0.39
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619068 0.92 MET (0.42) CREBBPHSD17B10MAPTHTR2AHDAC1
SCHEMBL29619180 0.91 KDM4E (0.47) ALOX15HSD17B10MAPTAKR1C3HTR2A
SCHEMBL29619053 0.89 KHK (0.43) CREBBPHSD17B10CHRNB2CHRNA4SLC6A2
SCHEMBL31677922 0.89 CHRNB2 (0.42) CHRNB2CHRNA4
SCHEMBL29619061 0.89 CREBBP (0.37) CREBBPALOX15HSD17B10CHRNB2CHRNA4
SCHEMBL29619123 0.88 CREBBP (0.37) CREBBPALOX15HSD17B10CHRNB2CHRNA4
SCHEMBL29619137 0.88 CREBBP (0.39) CREBBPCHRNB2CHRNA4
SCHEMBL29619060 0.87 CHRNB2 (0.40) LMNAHSD17B10CHRNB2CHRNA4MAPT
SCHEMBL29619050 0.87 CHRNB2 (0.40) LMNAHSD17B10CHRNB2CHRNA4MAPT
SCHEMBL29619002 0.87 CHRNB2 (0.37) CREBBPCHRNB2CHRNA4AKR1C3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO HTR2A, HTR5A, HTR1A LMNA 2981/4885CREBBP 2282/4885ALOX15 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.